In 2021, a large number of multinational pharmaceutical companies will spend huge amounts of money on TV advertising

New data released by iSpot.
tv recently revealed the ten drugs with the most ad spend in 2021
.
The ten drugs are Sanofi and Regeneron's anti-inflammatory drug Dupixen, Novo Nordisk's oral hypoglycemic drug Rybelsus, AbbVie's oral JAK inhibitor Rinvoq, Novo Nordisk's hypoglycemic drug Ozempic Megglutide subcutaneous injection), Eli Lilly’s Trulicity, Boehringer Ingelheim and Lilly’s antidiabetic Jardiance, AbbVie’s Skyrizi, Otsuka and Lundbeck’s antidepressant Rexulti, and Johnson & Johnson’s anti-inflammatory drug Tremfya
.
Of these, most are autoimmune drugs and diabetes drugs
.
It is worth noting that compared to 2020 as a whole, most companies have seen new growth in advertising spending on these drugs
.
On the list, there are two drugs with more than $200 million in ad spend in 2021
.
Sanofi and Regeneron's anti-inflammatory drug Dupixent, an autoimmune drug for asthma and atopic dermatitis, respectively, saw TV ad spending increase to $287.
6 million from $228.
4 million in 2020
.
The other is Novo Nordisk's new oral hypoglycemic drug Rybelsus (semaglutide oral tablet)
.
It is understood that the drug, as an adjunct to diet control and exercise, can be used to improve blood sugar control in adult patients with type 2 diabetes whose blood sugar levels are not adequately controlled
.
Ad spending for the drug jumped to $225.
2 million from $61 million in 2020, a 269% increase from the previous year
.
In this regard, the industry believes that this is due to Novo Nordisk's increased listing efforts
.
The drug with the largest increase in ad spending on the list is Johnson & Johnson's anti-inflammatory drug Tremfya
.
Spending on the drug nearly doubled to $105.
7 million in 2021, compared with $53.
8 million the previous year
.
Data show that Tremfya is the first approved selective IL-23 inhibitor
.
IL-23 is a cytokine that plays a key role in a variety of autoimmune diseases
.
Tremfya is also currently being developed for the treatment of other autoimmune diseases, including Crohn's disease (stage IIb/III), ulcerative colitis (stage IIb/III), and hidradenitis suppurativa (stage II)
.
In addition, Tremfya has been approved in several countries and regions around the world for the treatment of adults with moderate to severe plaque psoriasis
.
In China, Tremfya was approved for listing in Hong Kong in November 2018, and it was also declared for listing in China in late June 2019
.
In addition to Tremfya, AbbVie's oral JAK inhibitor Rinvoq has also increased year-on-year in advertising spending, rising from $122.
6 million in 2020 to $165 million
.
It is understood that AbbVie is currently working to increase Rinvoq's advertising spending to enhance public attention to Rinvoq
.
And this is mainly in response to the inevitable huge loss of sales caused by Humira facing the impact of biosimilars in the US market in the next few years
.
Of course, it is worth mentioning that there are also some drugs in 2021 that have been reduced in advertising spending
.
For example, AbbVie on the list has reduced ad spending for two products, including a total of $176.
4 million spent on Humira TV ads in 2021, a 50% drop from the previous year's $346.
4 million
.
Separately, only $121.
3 million was spent on Skyrizi, down 3.
9 percent from $126.
2 million the previous year
.